Intercellular adhesion molecule 2 as a novel prospective tumor suppressor induced by ERG promotes ubiquitination-mediated radixin degradation to inhibit gastric cancer tumorigenicity and metastasis.

Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2003-

Stomach Neoplasms*/genetics; Humans ; Prospective Studies ; Ubiquitination ; Cell Adhesion Molecules ; Transcriptional Regulator ERG

Background: Gastric cancer (GC) is a fatal cancer with unclear pathogenesis. In this study, we explored the function and potential mechanisms of intercellular adhesion molecule 2 (ICAM2) in the development and advancement of GC.
Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were performed to quantify ICAM2 expression in harvested GC tissues and cultured cell lines. Immunohistochemical analyses were conducted on a GC tissue microarray to quantify ICAM2 expression and explore its implication on the prognosis of GC patients. In vitro experiments were carried out to reveal the biological functions of ICAM2 in GC cell lines. Further, in vivo experiments were conducted using xenograft models to assess the impact of ICAM2 on GC development and metastasis. Western blot, immunofluorescence, immunoprecipitation, luciferase assay, chromatin immunoprecipitation, and ubiquitination analysis were employed to investigate the underlying mechanisms.
Results: ICAM2 expression was downregulated in GC, positively correlating with advanced T stage, distant metastasis, advanced clinical stage, vessel invasion, and shorter patient survival time. ICAM2 overexpression suppressed the proliferation, migration, invasion, metastasis of GC cells as well as their ability to form tumors, whereas ICAM2 knockdown yielded opposite results. Erythroblast transformation-specific-related gene (ERG) as a transcription factor promoted the transcription of ICAM2 by binding to the crucial response element localized within its promoter region. Further analysis revealed that ICAM2 reduced radixin (RDX) protein stability and expression. In these cells, ICAM2 bound to the RDX protein to promote the ubiquitination and degradation of RDX via NEDD4 Like E3 Ubiquitin Protein Ligase (NEDD4L), and this post-translational modification resulted in the inhibition of GC.
Conclusions: In summary, this study demonstrates that ICAM2, which is induced by ERG, suppresses GC progression by enhancing the ubiquitination and degradation of RDX in a NEDD4L-dependent manner. Therefore, these results suggest that ICAM2 is a potential prognostic marker and a therapeutic target for GC.
(© 2023. BioMed Central Ltd., part of Springer Nature.)

Asian Pac J Cancer Prev. 2014;15(22):9805-12. (PMID: 25520109)
J Cell Sci. 2012 Jul 15;125(Pt 14):3310-9. (PMID: 22467863)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cell Physiol Biochem. 2016;39(6):2509-2521. (PMID: 27855404)
Br J Cancer. 2008 Apr 22;98(8):1357-65. (PMID: 18349842)
Science. 2021 Oct;374(6563):eabf3066. (PMID: 34591612)
Cancer Sci. 2020 Nov;111(11):4061-4074. (PMID: 32639665)
Blood. 2005 Sep 1;106(5):1636-43. (PMID: 15920013)
Clin Cancer Res. 2015 Jun 1;21(11):2569-79. (PMID: 25754347)
J Cell Sci. 2014 Jan 15;127(Pt 2):267-75. (PMID: 24421310)
Clin Cancer Res. 2004 Jul 15;10(14):4885-92. (PMID: 15269165)
J Immunother Cancer. 2022 Jul;10(7):. (PMID: 35790315)
J Cell Sci. 2014 Feb 1;127(Pt 3):620-9. (PMID: 24317296)
J Cell Physiol. 2019 Mar;234(3):2659-2671. (PMID: 30132864)
Cell Commun Signal. 2014 Mar 04;12:12. (PMID: 24593809)
Biomolecules. 2021 Apr 12;11(4):. (PMID: 33921267)
Oncol Rep. 2012 Mar;27(3):700-6. (PMID: 22089331)
PLoS One. 2008;3(11):e3629. (PMID: 18978946)
Oncogene. 2015 Mar 19;34(12):1553-62. (PMID: 24704826)
Blood. 2006 Jun 15;107(12):4721-7. (PMID: 16469869)
Curr Opin Cell Biol. 2011 Aug;23(4):377-82. (PMID: 21592758)
BMC Cancer. 2013 May 28;13:261. (PMID: 23714211)
Front Immunol. 2020 Jan 14;10:3056. (PMID: 31993059)
Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188753. (PMID: 35752404)
JAMA Netw Open. 2021 Nov 1;4(11):e2135340. (PMID: 34797369)
Gastrointest Endosc. 2022 May;95(5):864-872. (PMID: 34998795)
Mol Cell. 2015 Sep 17;59(6):917-30. (PMID: 26344095)
Int J Mol Sci. 2022 Sep 20;23(19):. (PMID: 36232317)
Nat Rev Urol. 2012 Feb 14;9(3):131-7. (PMID: 22331093)
J Exp Med. 2017 Nov 6;214(11):3435-3448. (PMID: 28939548)
Cancer Lett. 2017 May 1;393:129. (PMID: 28137419)
Gastroenterology. 2021 Jul;161(1):116-127.e8. (PMID: 33744306)
Sci Rep. 2017 Jul 4;7(1):4613. (PMID: 28676638)
Sci Transl Med. 2016 Jun 8;8(342):342ra80. (PMID: 27280687)
Oncogene. 2012 Oct 18;31(42):4509-16. (PMID: 22179828)
ScientificWorldJournal. 2014;2014:340271. (PMID: 25136657)
JAMA Netw Open. 2022 Aug 1;5(8):e2227667. (PMID: 35984658)
Oncotarget. 2016 Sep 20;7(38):61426-61437. (PMID: 27556181)
J Clin Oncol. 2023 Mar 1;41(7):1470-1491. (PMID: 36603169)
Cancer Commun (Lond). 2021 Aug;41(8):747-795. (PMID: 34197702)
Ther Adv Hematol. 2022 Oct 28;13:20406207221132346. (PMID: 36324489)
Asian Pac J Cancer Prev. 2012;13(3):753-9. (PMID: 22631643)
Gastroenterology. 2011 Jan;140(1):310-21. (PMID: 20955708)
Immunol Rev. 2013 Nov;256(1):63-79. (PMID: 24117813)

Keywords: GC; ICAM2; Post-translational modifications; Transcription factor

144517-21-5 (radixin)
0 (Cell Adhesion Molecules)
0 (ERG protein, human)
0 (Transcriptional Regulator ERG)

Date Created: 20230927 Date Completed: 20230929 Latest Revision: 20231123

20231123

PMC10536727

10.1186/s12967-023-04536-2

37759298